Clinical Trial Update: Phase II Study of BI 2536 in Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase II study of BI-2536 in prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BI-2536

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED